{"entity":{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","aka":[],"tldr":"Every radioactive treatment leaves behind radioactive waste, such as used vials and, for a short time, the patient's own urine, which has to be safely stored until it stops being radioactive. The rules and the physical space needed for this differ from hospital to hospital and country to country, and building enough of that safe storage takes time.","summary":"US NRC rule 10 CFR 35.92 allows medical licensees to hold low-level radioactive waste for 'decay-in-storage' -- keeping it until a survey shows its radiation level is indistinguishable from background, then disposing of it as ordinary or medical waste -- but only for byproduct material with a physical half-life under 120 days. Most therapeutic isotopes qualify (lutetium-177's 6.65-day half-life decays in weeks), but contaminants complicate this: NRC guidance on Lutathera and Pluvicto notes that the metastable isotope lutetium-177m, with a 161-day half-life, can be present at roughly 0.02% of total activity and, when detected, must instead be handled as formal low-level radioactive waste under 10 CFR Part 20, a different and more burdensome disposal route.\n\nLow-level radioactive waste itself is classified by the NRC into Classes A, B and C by hazard; Class A, the least hazardous, makes up about 96% of total LLRW volume. A UK health-system readiness review lists radioactive-waste management -- decay-tank capacity, shielded 'hot' toilets for patients who have received a therapeutic dose, and staying within site-specific disposal limits -- as one of five mandatory steps any facility must have in place before it can deliver radioligand therapy at all, alongside licensing, imaging, treatment planning and follow-up.\n\nRegulatory fragmentation adds friction on top of the physical constraint: in the US, medical radioactive-material licensing is split between the NRC directly and 39 'Agreement States' that have taken on their own licensing authority, so requirements are not identical nationwide, and a site opening a new radioligand therapy programme must navigate whichever regime applies locally, often adding months to programme start-up alongside the physical build-out of shielded waste storage.","asOf":"2026-09-22","links":[{"label":"NRC: Decay-in-storage (DIS) of low-level radioactive waste, toolbox guidance","url":"https://www.nrc.gov/materials/toolboxes/llrw/decay-in-storage"},{"label":"NRC STC-22-074: Medical use, radiation safety and waste guidance for Lu-177 (Lutathera/Pluvicto)","url":"https://scp.nrc.gov/asletters/tech/sp22074.pdf"},{"label":"NRC: Low-level radioactive waste (LLRW) toolbox overview and classification","url":"https://www.nrc.gov/materials/toolboxes/llrw-waste"},{"label":"Establishing a robust radioligand therapy programme (licensing and Agreement State detail)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10905220/"},{"label":"Health system readiness for radioligand therapy in the UK: service provision","url":"https://www.healthsystemreadiness.com/app/uploads/Health-system-readiness-for-radioligand-therapy-in-the-UK-Service-provision.pdf"}],"tags":["regulation","waste disposal","radiation safety"],"related":["b-hot-lab-capacity","b-site-readiness-referral","lu-177"],"indications":[],"sections":[],"technologies":["radiopharmaceutical-gmp-release","radiopharmacy-network","lu177-radioligand-therapy"],"targets":[],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"stage":"regulation-manufacturing","severity":"moderate","metrics":[{"label":"Maximum half-life NRC allows for medical decay-in-storage of radioactive waste (10 CFR 35.92)","value":"under 120 days","url":"https://www.nrc.gov/materials/toolboxes/llrw/decay-in-storage"},{"label":"Lutetium-177m contaminant activity in Lutathera/Pluvicto (161-day half-life, requires formal LLW disposal if detected)","value":"~0.02% of total Lu-177 activity","url":"https://scp.nrc.gov/asletters/tech/sp22074.pdf"},{"label":"Share of total US low-level radioactive waste volume that is Class A (least hazardous)","value":"~96%","url":"https://www.nrc.gov/materials/toolboxes/llrw-waste"},{"label":"US states with their own ('Agreement State') authority to license medical radioactive materials, as of 2024","value":"39 states","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10905220/"}],"causes":["Decay-tank and shielded-toilet capacity is a fixed physical build-out at each site, so it does not scale automatically with rising patient volume.","US medical radioactive-material licensing is split between the NRC and 39 individual Agreement States, producing inconsistent requirements across the country.","Longer-lived contaminants generated during isotope production (such as lutetium-177m) fall outside the simple decay-in-storage rule and require a separate, more burdensome low-level-waste disposal pathway.","New alpha-emitter therapies introduce longer-lived daughter radionuclides in the decay chain, which existing decay-in-storage assumptions built around beta emitters do not automatically cover."],"currentEfforts":["NRC Regulatory Issue Summary 2004-17 (revised) clarifying performance-based decay-in-storage criteria, removing the older fixed ten-half-life holding requirement in favour of a background-radiation survey standard.","Site-level engineering firms offering modular decay-tank retrofits to expand waste-storage capacity without a full facility rebuild.","UK and other national health-system readiness frameworks setting out waste-management capacity as an explicit, checkable prerequisite for opening a radioligand therapy service."],"successLooksLike":"Harmonised, performance-based radioactive-waste rules that scale predictably with a site's radioligand therapy volume, so waste-handling capacity is planned alongside clinical capacity rather than becoming a late, site-specific licensing surprise."},"route":"/bottlenecks/b-radioactive-waste-regulation/","neighbours":{"bottleneck":[{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}]}}